Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes

被引：0
|
作者：
Yuxin Mu
Xuezhi Hao
Puyuan Xing
Xingsheng Hu
Yan Wang
Teng Li
Jinyao Zhang
Ziyi Xu
Junling Li
机构：
[1] National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Department of Medical Oncology
[2] Chinese Academy of Medical Sciences and Peking Union Medical College,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2020年 / 146卷
关键词：
Non-small-cell lung cancer; Osimertinib; T790M; Resistance mechanism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2427 / 2433
页数：6
相关论文
共 50 条
  • [1] Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes
    Mu, Yuxin
    Hao, Xuezhi
    Xing, Puyuan
    Hu, Xingsheng
    Wang, Yan
    Li, Teng
    Zhang, Jinyao
    Xu, Ziyi
    Li, Junling
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (09) : 2427 - 2433
  • [2] Clinical Outcomes of Various Resistance Mechanisms of Osimertinib in Chinese Advanced Non-Small Cell Lung Cancer Patients
    Xing, P.
    Mu, Y.
    Wang, S.
    Ma, D.
    Lin, J.
    Liu, H.
    Han-Zhang, H.
    Lizaso, A.
    Xiang, J.
    Mao, X.
    Hao, X.
    Li, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S396 - S396
  • [3] CircMYBL1 suppressed acquired resistance to osimertinib in non-small-cell lung cancer
    Li, Yaji
    Wang, Nan
    Huang, Yutang
    He, Shuai
    Bao, Meihua
    Wen, Chunjie
    Wu, Lanxiang
    CANCER GENETICS, 2024, 284-285 : 34 - 42
  • [4] Osimertinib for non-small-cell Lung Cancer
    Alakus, Hakan
    Zander, Thomas
    Bruns, Christiane
    ONKOLOGE, 2018, 24 (02): : 174 - 176
  • [5] Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer
    Schoenfeld, A. J.
    Antonia, S. J.
    Awad, M. M.
    Felip, E.
    Gainor, J.
    Gettinger, S. N.
    Hodi, F. S.
    Johnson, M. L.
    Leighl, N. B.
    Lovly, C. M.
    Mok, T.
    Perol, M.
    Reck, M.
    Solomon, B.
    Soria, J. -c.
    Tan, D. S. W.
    Peters, S.
    Hellmann, M. D.
    ANNALS OF ONCOLOGY, 2021, 32 (12) : 1597 - 1607
  • [6] Clinical outcomes of various resistance mechanisms of osimertinib in Chinese advanced non-small cell lung cancer patients.
    Xing, Puyuan
    Li Junling
    Hao, Xuezhi
    Mu, Yuxin
    Wang, Shouzheng
    Ma, Di
    Lin, Jing
    Liu, Hao
    Han Han-Zhang
    Lizaso, Analyn
    Xiang, Jianxing
    Mao, Xinru
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [7] Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer
    Shaikh, Matin
    Shinde, Yashodeep
    Pawara, Rahul
    Noolvi, Malleshappa
    Surana, Sanjay
    Ahmad, Iqrar
    Patel, Harun
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (02) : 1008 - 1046
  • [8] Re-administration of osimertinib in osimertinib-acquired resistant non-small-cell lung cancer
    Ichihara, Eiki
    Hotta, Katsuyuki
    Ninomiya, Kiichiro
    Kubo, Toshio
    Ohashi, Kadoaki
    Rai, Kammei
    Tanaka, Hisaaki
    Tabata, Masahiro
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    LUNG CANCER, 2019, 132 : 54 - 58
  • [9] ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non-small cell lung cancer
    Hou, Helei
    Sun, Dantong
    Zhang, Chuantao
    Liu, Dong
    Zhang, Xiaochun
    THORACIC CANCER, 2021, 12 (06) : 962 - 969
  • [10] Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study
    Lin, Chia-Chi
    Shih, Jin-Yuan
    Yu, Chong-Jen
    Ho, Chao-Chi
    Liao, Wei-Yu
    Lee, Jih-Hsing
    Tsai, Tzu-Hsiu
    Su, Kang-Yi
    Hsieh, Min-Shu
    Chang, Yih-Leong
    Bai, Ya-Ying
    Huang, Derek De-Rui
    Thress, Kenneth S.
    Yang, James Chih-Hsin
    LANCET RESPIRATORY MEDICINE, 2018, 6 (02): : 107 - 116
12345